
We will empower individuals with brain health conditions to have a choice over controlling their symptoms.
We use state-of-the-art brain imaging and brain stimulation techniques to investigate the neural processes that give rise to tics, the brain correlates of premonitory urges and the mechanisms of brain plasticity that might lead to the control or reduction of tics.
Our research suggests that the stimulation is suitable for anyone over 12 years of age. Additional research is currently being conducted to look at children who are younger than 12 years old
Our initial study demonstrated that stimulation was effective in reducing tic frequency in 75% of participants. The results of the clinical trial starting in 2022 will give a more accurate indication to the effectiveness of the technique.
We started the clinical trial in March 2022 and will run for approximately 10 months.
At the moment the clinical trial is full but there is a wait list that we can add your name to in case of any withdrawals. There are currently over 50 people on the wait list. The clinical trial is only open to people that live on the UK mainland (i.e. not Northern Ireland).
Unfortunately No. Our research investigating the use of median nerve stimulation to reduce tics in Tourette syndrome is a novel approach and there is currently no other clinical trials or similar research going on outside of the UK.
Most definitely. Our research team at the University of Nottingham is continuously conducting research aimed at understanding brain health conditions like Tourette syndrome and developing new treatment approaches. If you would like to volunteer to take part in these research studies, please take a look at the following link:
Company number: 13198315
Registered Office:
The Ingenuity Centre
University Of Nottingham Innovation Park
Triumph Road
Nottingham
England
NG7 2TU
Neupulse is a registered trade mark of Neurotherapeutics Ltd